Incyte’s frontMIND Hits in DLBCL – At a Toxicity Cost
Incyte’s Phase 3 frontMIND trial cut DLBCL progression risk 25% with tafasitamab + Revlimid + R-CHOP, but severe adverse events and deaths from toxicity ran ahead of standard care.
Healthcare & Biotech
Lantheus Weighs $7B Curium Bid; Radiopharm M&A Heats Up
Lantheus Holdings (LNTH) is weighing a roughly $7 billion takeover bid from PE-backed Curium Pharma. Shares jumped 9% on the report.